ELPIS trial plans to enrol stage I HER2-E BC patients to evaluate if surgery might be omitted if a complete response is achieved following neoadjuvant paclitaxel, trastuzumab, and pertuzumab. The gene discussed is ERBB2; the disease is breast cancer.